At present, etanercept represents the most commonly prescribed biologic agent for juvenile idiopathic arthritis (JIA) treatment. Children and adolescents with JIA are often treated with etanercept over long pe...
Authors:
Giulia Armaroli, Ariane Klein, Gerd Ganser, Michael J. Ruehlmann, Frank Dressler, Anton Hospach, Kirsten Minden, Ralf Trauzeddel, Ivan Foeldvari, Jasmin Kuemmerle-Deschner, Frank Weller-Heinemann, Andreas Urban and Gerd Horneff
Citation:
Arthritis Research & Therapy
2020
22:258
Content type: Research article
Published on: 29 October 2020